<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Phosphorylation of proline-rich Akt substrate of 40 kilodaltons at Thr246 (p-PRAS40Thr246) is a novel identified specific and stable biomarker for predicting phosphatidylinositol 3-kinase (PI3K) pathway activation and AKT inhibitor sensitivity. Objectives: We investigated the expression of p-PRAS40Thr246 in breast cancer, and their clinicopathological characteristics and prognostic significance. Methods: The expression of p-PRAS40Thr246 was detected by immunohistochemistry in 117 invasive breast cancer tumors. Results: p-PRAS40Thr246 was positive in 62 (53.0%) of 117 patients. p-PRAS40Thr246 expression was significantly associated with late tumor stages and shorter survival, but not with other clincopathological characteristics. Furthermore, p-PRAS40Thr246 was also an independent prognostic factor for invasive breast cancers. Conclusion: High prevalence of p-PRAS40Thr246 overexpression and its clinical significance in breast cancer suggests that this subgroup might benefit from PI3K inhibitors. We proposed that the detection of p-PRAS40Thr246 in breast cancer tissues should be included in the future clinical practice to develop patient-tailored treatments.</abstract>

Background: Phosphorylation of proline-rich Akt substrate of 40 kilodaltons at Thr246 (p-PRAS40Thr246) is a novel identified specific and stable biomarker for predicting phosphatidylinositol 3-kinase (PI3K) pathway activation and AKT inhibitor sensitivity. Objectives: We investigated the expression of p-PRAS40Thr246 in breast cancer, and their clinicopathological characteristics and prognostic significance. Methods: The expression of p-PRAS40Thr246 was detected by immunohistochemistry in 117 invasive breast cancer tumors. Results: p-PRAS40Thr246 was positive in 62 (53.0%) of 117 patients. p-PRAS40Thr246 expression was significantly associated with late tumor stages and shorter survival, but not with other clincopathological characteristics. Furthermore, p-PRAS40Thr246 was also an independent prognostic factor for invasive breast cancers. Conclusion: High prevalence of p-PRAS40Thr246 overexpression and its clinical significance in breast cancer suggests that this subgroup might benefit from PI3K inhibitors. We proposed that the detection of p-PRAS40Thr246 in breast cancer tissues should be included in the future clinical practice to develop patient-tailored treatments.

Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer

Department of Breast and Thyroid Surgery,Affiliated Qianfoshan Hospital, Shandong University, Jinan 250014,

Department of Breast and Thyroid Surgery, Affiliated Qianfoshan Hospital, Shandong University, Jinan 250014,

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Background: Phosphorylation of proline-rich Akt substrate of 40 kilodaltons at Thr246 (p-PRAS40Thr246) is a novel identified specific and stable biomarker for...

Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer

Article Category: Brief communication (Original)

Publicado en línea: 04 feb 2017

Páginas: 573 - 577

DOI: https://doi.org/10.5372/1905-7415.0604.092

Palabras clave
Biomarker, PI3K pathway, PRAS40, phosphorylation, targeted therapy

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer

Article Category: Brief communication (Original)

Publicado en línea: 04 feb 2017

Páginas: 573 - 577

DOI: https://doi.org/10.5372/1905-7415.0604.092

Palabras claveBiomarker, PI3K pathway, PRAS40, phosphorylation, targeted therapy

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Palabras clave
Biomarker, PI3K pathway, PRAS40, phosphorylation, targeted therapy